Maxim Group Reiterates “$23.00” Price Target for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)
Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also weighed in on SCMP. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a strong sell rating to a hold rating in a report on Tuesday, July 4th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, June 23rd. Mizuho reiterated a buy rating and set a $14.00 price objective on shares of Sucampo Pharmaceuticals in a report on Tuesday, April 4th. Finally, Jefferies Group LLC dropped their price objective on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a hold rating on the stock in a report on Thursday, May 4th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $17.63.
Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 0.48% during trading on Wednesday, reaching $10.40. The company’s stock had a trading volume of 469,212 shares. The company’s market cap is $480.42 million. The stock’s 50-day moving average is $10.58 and its 200 day moving average is $10.73. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. During the same quarter in the prior year, the business earned $0.24 earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities analysts forecast that Sucampo Pharmaceuticals will post $1.02 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. LSV Asset Management increased its stake in Sucampo Pharmaceuticals by 11.4% in the first quarter. LSV Asset Management now owns 2,346,418 shares of the biopharmaceutical company’s stock valued at $25,810,000 after buying an additional 239,200 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock valued at $21,130,000 after buying an additional 103,986 shares during the last quarter. Vanguard Group Inc. increased its stake in Sucampo Pharmaceuticals by 48.9% in the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after buying an additional 478,226 shares during the last quarter. NEA Management Company LLC acquired a new stake in Sucampo Pharmaceuticals during the second quarter valued at approximately $13,214,000. Finally, Royce & Associates LP increased its stake in Sucampo Pharmaceuticals by 24.6% in the first quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock valued at $10,714,000 after buying an additional 192,000 shares during the last quarter. 55.82% of the stock is owned by institutional investors.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.